Full-Time
Develops genomic tests for cancer diagnosis
$32 - $36/hr
Mid
San Diego, CA, USA
Upload your resume to see how it matches 6 keywords from the job description.
PDF, DOC, DOCX, up to 4 MB
Veracyte specializes in cancer diagnostics by developing advanced genomic tests that assist in the early detection and diagnosis of various cancers. Their tests analyze genetic information from non-invasive samples, such as nasal swabs or tissue biopsies, providing crucial insights into the presence and progression of cancer. This allows healthcare providers, including hospitals and clinics, to make informed treatment decisions tailored to individual patients. Veracyte differentiates itself from competitors by focusing on non-invasive testing methods and continuously investing in research to expand its product offerings. The company's goal is to improve patient outcomes and enhance the efficiency of medical resources through accurate cancer diagnostics.
Company Size
501-1,000
Company Stage
IPO
Headquarters
San Francisco, California
Founded
2008
Help us improve and share your feedback! Did you find this helpful?
Performance Bonus
Stock Options
Remote Work Options
Proficio Capital Partners LLC invests $1.18 million in Veracyte, Inc. (NASDAQ:VCYT).
Veracyte (VCYT) announced multiple abstract presentations at the 40th Annual European Association of Urology Congress (EAU25) in Madrid, Spain, showcasing the clinical performance and utility of its Decipher tests for prostate and bladder cancer.
Veracyte, Inc. announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical utility of its Decipher Prostate and Decipher Bladder tests to help guide treatment for patients with prostate and bladder cancer.
HighTower Advisors LLC makes new investment in Veracyte, Inc. (NASDAQ:VCYT).
That's why Veracyte is testing their Decipher Prostate Genomic Classifier, an AI-based transcriptome genetic test that was developed using primarily White American males, on Black African American males to see if it offers clinicians an improvement over clinical factors alone in guiding prostate cancer treatment decisions.